Mounjaro / Zepbound (tirzepatide)
Revenue Exposure
2025 revenue growth and volume/price dynamics were primarily driven by Mounjaro and Zepbound, indicating heavy dependence on the tirzepatide franchise.
Relevance 98·Dependency 90·Confidence 98
Source evidence
“The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound.”
Anti-obesity medicines
Revenue Exposure
Anti-obesity medicines comprise a significant portion of revenues; payer coverage restrictions (opt-in by U.S. self-insured employers, non-coverage in some international markets) impact sales volumes.
Relevance 92·Dependency 80·Confidence 93
Source evidence
“Barriers to reimbursable patient access in some cases include default payer coverage restrictions for our medicines.”
McKesson, Cencora, Cardinal Health
Customer Exposure
Three U.S. wholesale distributors each account for a significant percentage of consolidated revenue, concentrating distribution risk.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue”
Inflation Reduction Act (IRA)
Regulatory Exposure
IRA government-set Medicare prices apply to Jardiance (2026) and Trulicity/Verzenio (2028), with more significant products expected to be selected, meaningfully influencing business strategies.
Relevance 90·Dependency 80·Confidence 96
Source evidence
“The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.”
Government price controls and reimbursement restrictions
Regulatory Exposure
Public and private pricing/reimbursement restrictions have already negatively affected and are expected to continue to negatively affect consolidated results.
Relevance 90·Dependency 70·Confidence 95
Source evidence
“These pressures have negatively affected and we expect will continue to negatively affect our consolidated results of operations.”
November 2025 U.S. government pricing agreements
Competitive Exposure
Voluntary agreements lower Medicaid/certain drug prices and expand U.S. obesity medicine access; revenues may be insufficient to offset pricing concessions, affecting demand and competitive positioning globally.
Relevance 85·Dependency 75·Confidence 94
Source evidence
“we may fail to adequately capitalize on the additional U.S. access to our obesity medicines resulting from these agreements, particularly if the revenues generated from such expanded access are insufficient to offset pricing concessions.”
Cardiometabolic/incretin R&D pipeline (orforglipron, retatrutide, efsitora)
Revenue Exposure
Extensive Phase 3 and submitted pipeline across obesity, T2D, and cardiovascular indications represents the primary future growth driver and replacement source for the company's long-term revenue.
Relevance 85·Dependency 70·Confidence 92
Source evidence
“Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.”
Incretins
Customer Exposure
Counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets could materially impact results, reputation, and compliant market participation.
Relevance 85·Dependency 60·Confidence 90
Source evidence
“we continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets that could materially impact us”
U.S. private payers and pharmacy benefit managers
Customer Exposure
U.S. private payers and PBMs negotiate access, price/rebate concessions, and pharmacy reimbursement rates, significantly impacting the market for the company's pharmaceuticals.
Relevance 80·Dependency 70·Confidence 93
Source evidence
“Private payers and pharmacy benefit managers in the U.S. continue to significantly impact the market for pharmaceuticals through negotiation of access, manufacturer price or rebate concessions and pharmacy reimbursement rates.”
U.S. government drug pricing and access voluntary agreement
Regulatory Exposure
Negotiation and implementation of the voluntary U.S. government agreement on drug pricing and access is a disclosed uncertainty affecting pricing and reimbursement.
Relevance 80·Dependency 60·Confidence 90
Source evidence
“negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access”
Research and development spending
Cost Driver
Increased R&D expenses partially offset 2025 net income growth, making R&D spend a key cost driver alongside marketing, selling, and administrative expenses.
Relevance 75·Dependency 65·Confidence 90
Source evidence
“Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.”
Tariffs
Geopolitical Exposure
Regional/single-source supply dependencies accentuate tariff-related costs; tariffs listed first among external environmental factors raising distribution, construction, and procurement costs.
Relevance 75·Dependency 60·Confidence 90
Source evidence
“Regional or single-source dependencies may in some cases accentuate risks and costs (e.g., tariffs) related to manufacturing and supply.”
Biosimilar regulation
Regulatory Exposure
Guidelines and legislative actions easing biosimilar entry could materially affect the business given the importance of marketed and pipeline biologic products.
Relevance 75·Dependency 55·Confidence 90
Source evidence
“Given the importance to us of marketed biologic products and those in our clinical-stage pipeline, such regulation could have a material adverse effect on our business.”
Product sales customers
Customer Exposure
Net product revenue of $60,958M in 2025 is recognized when customers obtain control of goods, generally at shipment, with 30-70 day payment terms.
Relevance 70·Dependency 60·Confidence 90
Source evidence
“Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer.”
340B program, insulin access, and pricing litigation
Legal Exposure
Litigation and investigations related to the 340B program, access to insulin, pricing, and product safety could adversely impact the business if resolved adversely.
Relevance 70·Dependency 60·Confidence 90
Source evidence
“we are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters that, if resolved adversely to us, could negatively impact our business and consolidated results of operations.”
China
Competitive Exposure
China-based and similar markets' expanded R&D capabilities increase competitive pressure, including licensing to multinationals and direct competition in major markets.
Relevance 70·Dependency 50·Confidence 90
Source evidence
“We face intensifying competition worldwide, including from China and other markets that have significantly expanded and accelerated research and development capabilities.”
Tariffs / trade protection measures
Regulatory Exposure
Tariff exemptions for pharmaceuticals may be terminated; additional restrictions could disrupt supply and increase costs, which the company cannot meaningfully pass on.
Relevance 65·Dependency 55·Confidence 92
Source evidence
“Given the nature of pharmaceutical regulation and commercialization, we may not be able to share the burden of increased costs from tariffs and related impacts to any meaningful degree.”
LillyDirect
Revenue Exposure
LillyDirect direct-to-patient platform is a growing revenue channel in 2025, with new initiatives potentially exposing the company to new or exacerbated risks.
Relevance 65·Dependency 35·Confidence 88
Source evidence
“Sales through LillyDirect represented a growing portion of our business in 2025 and we have launched, and continue to explore, new partnerships and tools”
Boehringer Ingelheim
Revenue Exposure
Collaboration and other revenue includes revenue from the collaboration with Boehringer Ingelheim plus sale of product rights.
Relevance 65·Dependency 5·Confidence 90
Source evidence
“Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim”
Artificial intelligence
Technology Dependency
AI use in operations and partnerships may exacerbate competitive, regulatory, litigation, and cybersecurity risks.
Relevance 60·Dependency 45·Confidence 85
Source evidence
“the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties”
Non-U.S. subsidiary results are translated at weighted-average rates and net assets at period-end rates, with translation effects recorded in other comprehensive income ($1,241M favorable in 2025).
Relevance 60·Dependency 40·Confidence 85
Source evidence
“The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted-average currency rate for the period.”
Skilled talent competition
Cost Driver
Competition for qualified scientific, technical, and management personnel from multinationals, academia, and nearby employers has increased and may continue to increase labor costs.
Relevance 60·Dependency 40·Confidence 85
Source evidence
“which has increased and may continue to increase our labor costs”
United Kingdom
Revenue Exposure
Disclosed forward-looking risk includes fluctuations in foreign currency exchange rates, interest rates, and inflation/deflation affecting global operations across ~90 countries.
Relevance 55·Dependency 40·Confidence 70
Source evidence
“fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation”